Skip To Main Content
Anna Yssel on Muck Rack

Anna Yssel

As seen in: Nature, PLOS
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Anna Yssel’s profile

Articles by Anna Yssel

Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials

|
By Carolyn Williamson, Nonhlanhla N. Mkhize, Elena Giorgi, Craig A Magaret, Bronwen E. Lambson, Sinethemba Bhebhe, Haajira Kaldine, Thandeka Moyo-Gwete, Morgane Rolland, Raabya Rossenkhan, Nina Garcia Verified, Chivonne Moodley, Anna Yssel, Yunda Huang, Daniel Reeves, Bryan Mayer, Roger E. Bumgarner, Nicolas Beaume, Dylan Westfall, Michal Juraska, Allan C. deCamp, Hugh Murrell, Hongjun Bai, Wenjie Deng, Alec Pankow, Tanmoy Bhattacharya, Talita York, Nonkululeko Ndabambi, Lennie Chen, Hong Zhao, Ruwayhida Thebus, Paula Cohen, Ben Murrell, Shelly Karuna, John Hural, Nyaradzo Mgodi, Srilatha Edupuganti, Lynn Morris, David C. Montefiori, M. Juliana McElrath, Myron Cohen, Lawrence Corey, Paul T. Edlefsen, Peter Gilbert, Penny Moore, James Mullins, Lyle Curry, Alaine A. Marsden, Asanda Gwashu-Nyangiri
| Nature Verified
Abstract Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody-Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bnAb VRC01 blocked acquisition by VRC01-sensitive strains. However, its influence on viral evolution post acquisition is not fully understood.
Open in Who Shared Issue with article?

Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection

|
By James Mullins, Wenjie Deng, Elena Giorgi, Craig A Magaret, Morgane Rolland, Tanmoy Bhattacharya, Dylan Westfall, Anna Yssel, Roger E. Bumgarner, Ben Murrell, Thumbi Ndung’u, Merlin L. Robb, Raabya Rossenkhan, Paul T. Edlefsen, Krista L Dong, Lennie Chen, Asanda Gwashu-Nyangiwe, Hong Zhao, Ruwayhida Thebus, Nonkululeko Ndabambi, Sorachai Nitayaphan, Talita York, David Matten, Hugh Murrell, Alec Pankow, Michal Juraska, James Ludwig, John Hural, Myron Cohen, Lawrence Corey, M. Juliana McElrath, Peter Gilbert, Carolyn Williamson, Bruna Galvao, Fredrick Sawe
| Nature Verified
Abstract Understanding the selective forces acting upon HIV early in infection is crucial to design prevention strategies. By leveraging deep sequencing and the short diagnostic intervals of the FRESH and RV217 cohorts between the last-negative and first-positive RNA tests (median 4 days), we captured a precise and early snapshot of acute HIV infection.
Open in Who Shared Issue with article?

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials

|
By Carolyn Williamson, Chivonne Moodley, Craig A Magaret, Elena Giorgi, Morgane Rolland, Dylan Westfall, Anna Yssel, Wenjie Deng, Nonhlanhla N. Mkhize, Lennie Chen, Hong Zhao, Tanmoy Bhattacharya, Alec Pankow, Ben Murrell, Ruwayhida Thebus, Paula Cohen Verified, Bronwen E. Lambson, Michal Juraska, Hongjun Bai, Allan C. deCamp, Maurine D Miner, James Ludwig, Yunda Huang, Lily Zhang, Daniel Reeves, Bryan Mayer, Shelly Karuna, John Hural, Lynn Morris, David C. Montefiori, Penny Moore, Paul T. Edlefsen, Srilatha Edupuganti, Nyaradzo Mgodi, M. Juliana McElrath, Myron Cohen, Lawrence Corey, Peter Gilbert, James Mullins, Raabya Rossenkhan, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Haajira Kaldine, Sinethemba Bhebhe, Cindy Molitor, Nicolas Beaume, David Matten, Roger E. Bumgarner
| Nature Verified
Abstract In the antibody mediated prevention (AMP) trials, the broadly neutralizing antibody (bNAb) VRC01 demonstrated protective efficacy against susceptible HIV strains. To understand how VRC01 shaped breakthrough infections, deep sequencing was performed on 172 participants (>100,000 gag-Δpol and rev-env-Δnef sequences), at diagnosis and over time, in the placebo and treatment arms of the African (HVTN703/HPTN081; NCT02568215) and Americas/Europe (HVTN704/HPTN085; NCT02716675) cohorts.
Open in Who Shared Issue with article?

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials

|
By Nonhlanhla N. Mkhize, Cape Town, Anna Yssel, PLOS Pathogens
| PLOS
Neutralization profiles of AMP placebo viruses Next, we focused on the pseudoviruses in the placebo arms (n = 76) for both AMP trials (hereafter referred to as “AMP placebo viruses”) and generated a hierarchical clustering heatmap comparing viral neutralization against the same bnAbs (Fig 3). We did not include viruses in the VRC01 arm in this analysis as antibody pressure may have led to selection [18].
Open in Who Shared Issue with article?
Show More